Tag: HAV
Acellular tissue-engineered vessel granted FDA Regenerative Medicine Advanced Therapy designation for...
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational...
Humacyte submits Biologics License Application to FDA seeking approval of Human...
Humacyte today announced that it has submitted a Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking approval of the Human...
Humacyte announces positive top line results from Phase 2/3 trial of...
Humacyte has announced positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair.
A...
Clinical performance of Human Acellular Vessel amid war in Ukraine presented...
Clinical outcomes of Humacyte's investigational Human Acellular Vessel (HAV) were presented at the Military Health System Research Symposium in Kissimmee, Florida (Aug. 14–17), following...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrollment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...
Humacyte completes enrolment in Phase II/III trial of Human Acellular Vessel...
Humacyte today announced completion of enrolment in its Phase II/III vascular trauma trial (V005) that is expected to support a Biologics License Application (BLA)...